top of page


Brazil approves Henlius and Organon's pertuzumab biosimilar for HER2-positive breast cancer
Brazil's health regulator has approved Henlius and Organon's pertuzumab biosimilar for certain HER2-positive breast cancer patients, marking the country's first authorisation of a biosimilar to this established oncology antibody.

nuaxia
Nov 102 min read


Sobi moves to acquire full control of Pint Pharma to expand Latin American rare disease platform
The transaction would give Sobi full ownership of a specialist commercialisation platform spanning seven Latin American markets, building on its $105 million investment in Pint Pharma in 2025.

nuaxia
Aug 103 min read
bottom of page